Associate Professor, Internal Medicine (Hematology/Oncology), University of Pittsburgh
Oncology
Julie E. Bauman, MD is an expert in the field of Oncology. She researched medicine at Tufts University School of Medicine. Tufts University School of Medicine is ranked 49/52 in Research/PrimaryCare. Doctor Julie E. Bauman, MD has written publications. She has 21 publications published with PubMed. The lastest publication is: 'Oral Cancer Chemoprevention-The End of EPOC, the Beginning of an Epoch of Molecular Selection.' Julie Bauman is registered with Medicare.
Publications
- Oral Cancer Chemoprevention-The End of EPOC, the Beginning of an Epoch of Molecular Selection.
- An enhanced role for palliative care in the multidisciplinary approach to high-risk head and neck Cancer.
- A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous Cell car...
- Molecular Characterization of Apocrine Salivary Duct Carcinoma.
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
- Disease-specific survival for patients with multiple Myeloma: significant improvements over time in all age groups.
- A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic ...
- Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck Cancer.
- Salivary Duct Carcinoma and the Concept of "Early carcinoma ex Pleomorphic Adenoma"
- Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes.
- ERCC1 is a prognostic biomarker in locally advanced head and neck Cancer: results from a randomised, phase II trial.
- Symptomatic reduction in free testosterone levels secondary to crizotinib use in male Cancer patients.
- Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial.
- A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous Cell carcinoma.
- Relationship of protein and calorie intake to the severity of oral mucositis in patients with head and neck Cancer receiving radiation therapy.
- Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid Cancer and metastatic medullary carcinoma of the thyroid with functiona...
- Antagonism of platelet-derived growth factor receptor in non small cell lung Cancer: rationale and investigations.
- Treatment of recurrent squamous Cell carcinoma of the skin with cetuximab.
- Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung Cancer: surgical and oncologic outcomes.
- A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Schools
Procedures Preformed
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Washington
-
University of Utah
-
Tufts University School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER |
|
1164431748 |
| NPPES Provider LastName |
|
BAUMAN |
| NPPES Provider FirstName |
|
JULIE |
| NPPES Provider ZIPCode |
|
871024517 |
| NPPES Provider State |
|
NM |
| Specialty Description |
|
Hematology/Oncology |
| Total Claim Count |
|
46.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1164431748 |
| Last Name Of The Provider |
BAUMAN |
| First Name Of The Provider |
JULIE |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.